Kiovig

Human Normal Immunoglobulin, the active ingredient in Kiovig, is an immunoglobulin presented as a solution for injection for intravenous use. It is used to replace deficient IgG antibodies in primary and secondary immunodeficiency, idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. GNH USA supplies Kiovig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Kiovig is employed in immune‑mediated disorders where IgG replacement is required.

Primary immunodeficiency diseases: provides IgG replacement to reduce infection frequency. Secondary immunodeficiency (e.g., chemotherapy): restores IgG levels to support immune function. Idiopathic thrombocytopenic purpura: modulates immune response to increase platelet count. Chronic inflammatory demyelinating polyneuropathy: attenuates autoimmune attack on peripheral nerves.

Adverse reactions may occur with intravenous immunoglobulin therapy.

Common Side Effects: - Headache - Fever or chills - Fatigue - Nausea - Infusion‑related flushing or itching - Mild hypertension

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions - Thromboembolic events (e.g., deep‑vein thrombosis) - Acute renal failure or tubular necrosis - Aseptic meningitis - Hemolytic anemia - Severe thrombocytopenia

Careful assessment and monitoring are required when using Kiovig.

Assess baseline IgG levels: determine need for replacement therapy. Monitor infusion reactions: observe patient during and after administration. Adjust infusion rate in renal impairment: slower rates reduce renal stress. Avoid in patients with anti‑IgA antibodies and IgA deficiency: risk of severe anaphylaxis. Use caution in hypercoagulable states: consider thrombosis risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kiovig may interact with other agents affecting immunity or coagulation.

Major Interactions (Avoid): - Live vaccines: reduced efficacy, may require postponement. - Concurrent blood products: increased viscosity, risk of circulatory overload.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR for potential alterations. - Diuretics: watch for fluid balance and renal function. - ACE inhibitors: possible additive hypotensive effect during infusion.